| Drug Name |
Phenelzine sulfate |
| Drug ID |
BADD_D01751 |
| Description |
Phenelzine, with the formula β-phenylethylhydrazine, is a monoamine oxidase inhibiting antidepressant that is effective in the treatment of panic disorder and social anxiety disorder.[A15753] It was developed by Parke Davis and originally FDA approved on June 9th, 1961. It is currently approved under prescription by the name of Nardil. |
| Indications and Usage |
A nonendogenous depression is characterized by a disturbance in mood and general outlook. The physical symptoms tend to be less severe and it often occurs in response to stressful life events that keep occurring over a large period of time generating a continuous stress in the daily living.[A31924] |
| Marketing Status |
Prescription |
| ATC Code |
N06AF03 |
| DrugBank ID |
DB00780
|
| KEGG ID |
D00505
|
| MeSH ID |
D010624
|
| PubChem ID |
61100
|
| TTD Drug ID |
D0P9AC
|
| NDC Product Code |
46016-1562; 59762-0119; 60862-004; 43386-360; 0071-0350 |
| Synonyms |
Phenelzine | beta-Phenylethylhydrazine | beta Phenylethylhydrazine | Fenelzin | Phenethylhydrazine | 2-Phenethylhydrazine | 2 Phenethylhydrazine | Phenelzine Sulfate | Sulfate, Phenelzine | Nardelzine | Nardil |
